Highest-materiality recent filing
Nu-Med Plus closes acquisition of six Canadian gold properties via Maritimes Gold Corp
Closing on Aug 20, 2026; issued 500,000 Series A Preferred shares to MegumaGold, convertible to up to 10M common shares (20 votes each).
Nu-Med Plus completes acquisition of Avid Gold; Fred Tejada gains voting control
Acquired 100% of Avid Gold Ltd for 4,500,000 Series A Preferred shares and assumption of $100,000 note.
Nu-Med Plus to acquire Avid Gold Ltd and six gold properties in Canada via share exchange
Acquires 100% of Avid Gold Ltd for 4,500,000 Series A Preferred shares and assumption of $100,000 debt.
YourSpace terminated share exchange agreement on Oct 28, 2024, failing to provide audited 2023 financials.
Nu-Med Plus completes acquisition of YourSpace America, new CEO and majority control shift
Nu-Med Plus acquires YourSpace America via share exchange; YSA becomes wholly owned subsidiary as of April 28, 2024.
Nu-Med Plus to merge with YourSpace America; YSA's Colvin to become CEO with majority voting control
4,500,000 Series A Preferred shares (20:1 voting, convertible into 20 common each) issued to YSA shareholders at closing.
CEO Jeffrey Robins resigns; William Hayde appointed as CEO and Chairman
Jeffrey L. Robins resigned as President, CEO, Director and Chairman on Sept 12, 2022; Dr. Brett J. Earl resigned as director.
On October 28, 2024, the Board of Directors appointed Mr. William Hayde, who is the Chairman of the Board, to serve as President/Chief Executive Officer of Nu-Med.
Mr. Colvin submitted his resignation from the positions to which he had been appointed.
Following the appointment of Mr. Colvin as President and Chief Executive Officer, the Company’s former President and CEO William Hayde was appointed to serve as the Company’s Executive Chairman of the Board.
the Board of Directors of the Company appointed William R. “Russ” Colvin as the Company’s President, Chief Executive Officer, and Director of the Company.
On October 18, 2022, the Board of Directors recognized the need for an additional member of the Board of Directors, and unanimously consented to appoint Jeffrey L. Robins to the Board of Director.
On September 12, 2022, Jeffrey L. Robins resigned as President, Chief Executive Officer, Director and Chairman of the Board
and Dr. Brett J. Earl resigned as a director.
The Corporation has appointed Mr. William Hayde as the President, Chief Executive Officer, Director and Chairman of the Board.
On December 31, 2021, Thomas Tate resigned as Vice President of Scientific Development and a director; William Moon resigned as Vice President of Technology and a director; and Dr. Craig Morrison resigned as Vice President of Research and a director.
Dr. Craig Morrison resigned as Vice President of Research and a director. Dr. Morrison is moving to a position on our Medical Advisory Board.
On December 31, 2021, Thomas Tate resigned as Vice President of Scientific Development and a director; William Moon resigned as Vice President of Technology and a director; and Dr. Craig Morrison resigned as Vice President of Research and a director.
Max materiality 0.90 · Median 0.60 · Most common event m_and_a